- Home
- TCRX vs CATO Comparison
TCRX vs CATO Comparison
Compare TCRX & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | CATO |
|---|---|---|
| Founded | 2018 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 61.6M |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TCRX | CATO |
|---|---|---|
| Price | $1.18 | $3.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 465.2K | 51.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.28 | ★ 17.09 |
| EPS | N/A | ★ 0.25 |
| Revenue | $10,325,000.00 | ★ $649,806,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $69.75 | N/A |
| P/E Ratio | ★ N/A | $12.36 |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $2.19 |
| 52 Week High | $2.57 | $4.92 |
Technical Indicators
Market Signals| Indicator | TCRX | CATO |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 45.65 |
| Support Level | $1.16 | $2.81 |
| Resistance Level | $1.23 | $3.22 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 71.80 | 23.08 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.